Concomitant ceftriaxone and high-concentration intravenous calcium therapy in adult critical care patients: A matched cohort study

Annals of Pharmacotherapy

Volumn 44, Issue 7-8, 2010, Pages 1158-1163

  Dalton, Bruce R ^a   Zuege, Danny J ^b   Shahpori, Reza ^a   Laupland, Kevin B ^b  

^a FOOTHILLS HOSPITAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Calcium; Cardiorespiratory failure; Ceftriaxone

Indexed keywords

CALCIUM CHLORIDE; CEFTRIAXONE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; CANADA; CONTINUOUS RENAL REPLACEMENT THERAPY; CRITICALLY ILL PATIENT; DRUG MEGADOSE; FEMALE; HUMAN; INTENSIVE CARE; INTENSIVE CARE UNIT; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OXYGENATION; PRIORITY JOURNAL; PROGNOSIS; CHEMICALLY INDUCED; COHORT ANALYSIS; CRITICAL ILLNESS; DRUG INTERACTION; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTIVARIATE ANALYSIS; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; STATISTICAL MODEL;

AGED; ALBERTA; ANTI-BACTERIAL AGENTS; CALCIUM CHLORIDE; CEFTRIAXONE; COHORT STUDIES; CRITICAL ILLNESS; DRUG INTERACTIONS; FEMALE; HOSPITAL MORTALITY; HUMANS; INFUSIONS, INTRAVENOUS; INTENSIVE CARE; LENGTH OF STAY; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RESPIRATORY INSUFFICIENCY; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 77954588359     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M745     Document Type: Article

References (26)

1. Important clarification of prescribing information (Rocephin). August 2007. www.fda.gov/MedWatch/safety/2007/Rocephin-HCP-august2007.pdf (accessed 2007 Nov 9).
2. Notice to hospitals; Health Canada issued important safety information on ceftriaxone (July 31, 2008). http://www.hc-sc.gc.ca/dhp-mps/alt-formats/ hpfb-dgpsa/pdf/medeff/ceftriaxone-nth-aah-eng.pdf (accessed 2009 Aug 10).
3. Bradley JS, Wassel RT, Lee L, et al. Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary events. Pediatrics 2009;123:609-13.
4. Postmarket drug safety information for patients and providers. Ceftriaxone (marketed as Rocephin and generics). http://www.fda.gov/Drugs/ DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm084263.htm (accessed 2009 Aug 10).
5. Notice to hospitals; Health Canada issued important safety information on ceftriaxone (Oct 15, 2009). http://www.hc-sc.gc.ca/dhp-mps/medeff/ advisories- avis/prof/-2009/ceftriaxone-2-nth-aah-eng.php (accessed 2009 Oct 24).
6. Shiffman ML, Keith FB, Moore EW. Pathogenesis of ceftriaxone-associated biliary sludge. Gastroenterology 1990;99:1772-8.
7. Park HZ, Lee SP, Schy AL. Ceftriaxone-associated gallbladder sludge: identification of calcium-ceftriaxone salt as a major component of gall-bladder precipitate. Gastroenterology 1991;100:1665-70.
8. Mohkam M, Karimi A, Gharib A, et al Ceftriaxone associated nephrolithiasis: a prospective study in 284 children. Pediatr Nephrol 2007;22: 690-4.
9. Avci Z, Koktener A, Uras N, et al. Nephrolithiasis associated with ceftriaxone therapy: a prospective study in 51 children. Arch Dis Child 2004; 89:1069-72.
10. Doig CJ, Zygun DA, Fick GH, et al. Study of clinical course of organ dysfunction in intensive care. Crit Care Med 2004;32:384-90.
11. Walter SD. Matched case-control studies with a variable number of controls per case. Appl Stat 1980;29:172-9.
12. Morrell M, Cannella C, Simpson S. Retrospective analysis of ceftriaxone and intravenous calcium administration at a university hospital (poster, abstract A-1876). Presented at: 48th Annual Interscience Conference of Antimicrobial Agents and Chemotherapy/Infectious Diseases Society of America 46th Annual Meeting, Washington, DC, October 25-28, 2008.
13. Steadman E, Raisch DW, Bennett CL, et al. Evaluation of a potential clinical interaction between ceftriaxone and calcium. Antimicrob Agents Chemother 2010;54:1534-40.
14. Stoeckel K, McNamara PJ, Brandt R, et al. Effects of concentration- dependent plasma protein binding on ceftriaxone kinetics. Clin Pharmacol Ther 1981;29:650-7.
15. Fukumoto K, Aida S, Oishi T, et al. Pharmacokinetics of ceftriaxone, a third-generation cephalosporin, in pediatric patients. Biol Pharm Bull 2009;32:1139-41.
16. Bektas S, Goetze B, Speer CP. Decreased adherence, chemotaxis and phagocytic activities of neutrophils from preterm neonates. Acta Paediatr Scand 1990;79:1031-8.
17. Kallman J, Schollin J, Schalen C, et al. Impaired phagocytosis and opsonisation towards group B streptococci in preterm neonates. Arch Dis Child Fetal Neonatal Ed 1998;78:F46-50.
18. Te Pas A, Davis PG, Hooper SB, et al. From liquid to air: breathing after birth. J Pediatr 2008;152:607-11.
19. Pierson DJ. Indications for mechanical ventilation in adults with acute respiratory failure. Respir Care 2002;47:249-65.
20. Dollery CM, Sullivan ID, Bauraind O, et al. Thrombosis and embolism in long-term central venous access for parenteral nutrition. Lancet 1994;344: 1043-5.
21. Reedy JS, Kuhlman JE, Voytovich M. Microvascular pulmonary emboli secondary to precipitated crystals in a patient receiving total parenteral nutrition: a case report and description of the high-resolution CT findings. Chest 1999;115:892-5.
22. Hill SE, Heldman LS, Goo ED, et al. Fatal microvascular pulmonary emboli from precipitation of a total nutrient admixture solution. JPEN J Parenter Enteral Nutr 1996;20:81-7.
23. Feigin DS. Talc: understanding its manifestations in the chest. AJR Am J Roentgenol 1986;146:295-301.
24. McCarroll KA, Roszler MH. Lung disorders due to drug abuse. J Thorac Imaging 1991;6:30-5.
25. Algorithm for early management of meningococcal disease in children. 6th ed. 2008. Meningitis Research Foundation. http:// www.meningitis. org/assets/x/50150 (accessed 2010 Feb 18).
26. WHO Drug Information 2008;22:193-4.